减持创新药，补换AI医疗！部分基金动向曝光

Core Viewpoint - The public fund's strategy of "first doing drugs, then doing medicine" is enhancing the net value of pharmaceutical-themed funds and creating switching opportunities [1] Group 1: Fund Performance and Strategy - In June and July, innovative drug-themed funds began to double in value, accelerating the demand for portfolio adjustments among public funds and boosting interest in AI healthcare [2][4] - As of August 17, medical-themed funds achieved a maximum return rate of nearly 150% within eight months, primarily driven by the "drug" segment [4] - Fund managers have started to reduce their positions in innovative drugs and shift towards AI healthcare stocks, indicating a strategic transition in the market [6][9] Group 2: Market Dynamics and Fund Manager Insights - Fund managers emphasize that innovative drugs and AI healthcare are at different developmental stages, with innovative drugs currently in a results realization phase, while AI healthcare is still exploring product validation and commercialization [5] - The shift towards AI healthcare is reflected in the significant stock price increases of AI healthcare companies, such as a 65% rise in the stock price of Crystal Technology within ten trading days [7] - Fund managers are increasingly optimistic about AI healthcare becoming a major investment theme by 2025, with a focus on companies that can leverage high-quality data for improved healthcare outcomes [10]